Functional (Non Ulcer) Dyspepsia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 36 Published: March 31, 2022 Report Code: GMDGDHC22030IDB

Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Signs and symptoms include burning sensation or discomfort in the upper abdomen or lower chest, sometimes relieved by food or antacids, bloating, belching, and nausea. Treatment includes medications to reduce acid production, antibiotics, and low-dose antidepressants.

The Functional (Non-Ulcer) Dyspepsia Drugs in Development market research report provides an overview of the Functional (Non Ulcer) Dyspepsia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Functional (Non-Ulcer) Dyspepsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Functional (Non-Ulcer) Dyspepsia and features dormant and discontinued projects.

What are the targets of the functional dyspepsia pipeline drugs market?

The targets of the functional dyspepsia pipeline drugs market are 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 1, Acetylcholinesterase, Bile Acid, Motilin Receptor, Phosphate, and Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K.

Functional dyspepsia pipeline drugs market, by targets

Functional dyspepsia pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the functional dyspepsia pipeline drugs market?

The mechanisms of action of the functional dyspepsia pipeline drugs market are 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1 Agonist, Acetylcholinesterase Inhibitor, Bile Acid Sequestrant, Motilin Receptor Agonist, Phosphate Binder, and Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K Inhibitor.

Functional dyspepsia pipeline drugs market, by mechanisms of action

Functional dyspepsia pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What is the route of administration in the functional dyspepsia pipeline drugs market?

The route of administration in the functional dyspepsia pipeline drugs market is oral.

What are the molecule types in the functional dyspepsia pipeline drugs market?

The molecule types in the functional dyspepsia pipeline drugs market are small molecule and polymer.

Functional dyspepsia pipeline drugs market, by molecule types

Functional dyspepsia pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the functional dyspepsia pipeline drugs market?

The key companies in the functional dyspepsia pipeline drugs market are RaQualia Pharma Inc, Daewoong Pharmaceutical Co Ltd, ISOThrive Inc, Mitsubishi Tanabe Pharma Corp, Renexxion LLC, and Zeria Pharmaceutical Co Ltd.

Functional dyspepsia pipeline drugs market, by key companies

Functional dyspepsia pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report overview

Targets 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 1, Acetylcholinesterase, Bile Acid, Motilin Receptor, Phosphate, and Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K
Mechanisms of Action 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 1 Agonist, Acetylcholinesterase Inhibitor, Bile Acid Sequestrant, Motilin Receptor Agonist, Phosphate Binder, and Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K Inhibitor
Route of Administration Oral
Molecule Types Small Molecule and Polymer
Key Companies RaQualia Pharma Inc, Daewoong Pharmaceutical Co Ltd, ISOThrive Inc, Mitsubishi Tanabe Pharma Corp, Renexxion LLC, and Zeria Pharmaceutical Co Ltd

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Functional (Non-Ulcer) Dyspepsia (Gastrointestinal).
  • Reviews of pipeline therapeutics for Functional (Non-Ulcer) Dyspepsia (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Key companies involved in Functional (Non-Ulcer) Dyspepsia (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • Assessment of Functional (Non-Ulcer) Dyspepsia (Gastrointestinal) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Functional (Non-Ulcer) Dyspepsia (Gastrointestinal).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Functional (Non-Ulcer) Dyspepsia (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Functional (Non-Ulcer) Dyspepsia (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • Daewoong Pharmaceutical Co Ltd

    ISOThrive Inc

    Mitsubishi Tanabe Pharma Corp

    RaQualia Pharma Inc

    Renexxion LLC

    Zeria Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Functional (Non Ulcer) Dyspepsia – Overview

Functional (Non Ulcer) Dyspepsia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Functional (Non Ulcer) Dyspepsia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Functional (Non Ulcer) Dyspepsia – Companies Involved in Therapeutics Development

Daewoong Pharmaceutical Co Ltd

ISOThrive Inc

Mitsubishi Tanabe Pharma Corp

RaQualia Pharma Inc

Renexxion LLC

Zeria Pharmaceutical Co Ltd

Functional (Non Ulcer) Dyspepsia – Drug Profiles

5-BIOP – Drug Profile

Product Description

Mechanism Of Action

acotiamide hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

colestilan chloride – Drug Profile

Product Description

Mechanism Of Action

ISOT-101 – Drug Profile

Product Description

Mechanism Of Action

mosapride SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

naronapride – Drug Profile

Product Description

Mechanism Of Action

History of Events

RQ-00000010 – Drug Profile

Product Description

Mechanism Of Action

History of Events

RQ-00201894 – Drug Profile

Product Description

Mechanism Of Action

tegoprazan – Drug Profile

Product Description

Mechanism Of Action

History of Events

Functional (Non Ulcer) Dyspepsia – Dormant Projects

Functional (Non Ulcer) Dyspepsia – Discontinued Products

Functional (Non Ulcer) Dyspepsia – Product Development Milestones

Featured News & Press Releases

Mar 25, 2013: Zeria Pharma Receives Approval For Acofide In Japan For Treating Functional Dyspepsia

Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Functional (Non Ulcer) Dyspepsia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Functional (Non Ulcer) Dyspepsia – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022

Functional (Non Ulcer) Dyspepsia – Pipeline by ISOThrive Inc, 2022

Functional (Non Ulcer) Dyspepsia – Pipeline by Mitsubishi Tanabe Pharma Corp, 2022

Functional (Non Ulcer) Dyspepsia – Pipeline by RaQualia Pharma Inc, 2022

Functional (Non Ulcer) Dyspepsia – Pipeline by Renexxion LLC, 2022

Functional (Non Ulcer) Dyspepsia – Pipeline by Zeria Pharmaceutical Co Ltd, 2022

Functional (Non Ulcer) Dyspepsia – Dormant Projects, 2022

Functional (Non Ulcer) Dyspepsia – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Functional (Non Ulcer) Dyspepsia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.